» Articles » PMID: 27478465

Searching for a Good Model for Systemic Sclerosis: the Molecular Profile and Vascular Changes Occurring in UCD-200 Chickens Strongly Resemble the Early Phase of Human Systemic Sclerosis

Overview
Journal Arch Med Sci
Specialty General Medicine
Date 2016 Aug 2
PMID 27478465
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Vascular injury and endothelial cell (EC) apoptosis are the earliest events in systemic sclerosis (SSc), before the onset of fibrosis, and stromal cell-derived factor 1 (SDF-1), vascular endothelial growth factor (VEGFA), endothelin-1 (ET-1) and platelet-derived growth factors (PDGF-BB) represent the key molecules to study the link between vascular injury and fibrosis during SSc. The University of California at Davis line 200 (UCD-200) chickens display the same hallmarks of human SSc: vascular occlusion, perivascular lymphocytic infiltration and fibrosis of skin and internal organs. In this study we assessed both cytokines and growth factors involved in the early phases of the UCD-200 chickens' skin lesions, to determine whether these animals might represent an appropriate experimental model to study the pathogenesis of SSc.

Material And Methods: Immunofluorescence analysis was performed on human SSc skin, human healthy control (hHC) skin, UCD-200 combs and HC H.B15 chicken (cHC) combs, using anti-SDF-1, CXCR4, VEGFA, VEGF receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2), ET-1, ET receptor A (ETAR), ET receptor B (ETBR), PDGF-BB, and PDGF receptor (PDGFR) antibodies. The plasma concentrations of SDF-1, VEGFA, ET-1 and PDGF-BB were determined by ELISA.

Results: All the molecules analyzed showed higher levels in SSc patients and UCD-200 chickens than in hHC and cHC. Furthermore, the levels of the assessed molecules paralleled the severity of comb involvement.

Conclusions: The molecular similarities between avian and human SSc, observed in this study, suggest that the UCD-200 chickens are an interesting model for translational approaches to SSc.

Citing Articles

Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.

Yang H, Cheong S, He Y, Lu F Stem Cell Res Ther. 2023; 14(1):372.

PMID: 38111001 PMC: 10729330. DOI: 10.1186/s13287-023-03543-w.


Identification of PDGFRα+ cells in uterine fibroids - link between angiogenesis and uterine telocytes.

Aleksandrovych V, Bereza T, Ulatowska-Bialas M, Pasternak A, Walocha J, Pitynski K Arch Med Sci. 2022; 18(5):1329-1337.

PMID: 36160340 PMC: 9479735. DOI: 10.5114/aoms.2019.86795.


Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts.

Liakouli V, Cipriani P, Di Benedetto P, Panzera N, Ruscitti P, Pantano I Sci Rep. 2019; 9(1):4589.

PMID: 30872612 PMC: 6418261. DOI: 10.1038/s41598-019-39485-8.


Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.

Di Benedetto P, Liakouli V, Ruscitti P, Berardicurti O, Carubbi F, Panzera N Arthritis Res Ther. 2018; 20(1):223.

PMID: 30285896 PMC: 6235209. DOI: 10.1186/s13075-018-1719-4.


Angiogenesis Dysregulation in the Pathogenesis of Systemic Sclerosis.

Cantatore F, Maruotti N, Corrado A, Ribatti D Biomed Res Int. 2017; 2017:5345673.

PMID: 28791304 PMC: 5534276. DOI: 10.1155/2017/5345673.

References
1.
Pablos J, Amara A, Bouloc A, Santiago B, Caruz A, Galindo M . Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol. 1999; 155(5):1577-86. PMC: 1866989. DOI: 10.1016/S0002-9440(10)65474-0. View

2.
Abraham D, Vancheeswaran R, Dashwood M, Rajkumar V, Pantelides P, Xu S . Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997; 151(3):831-41. PMC: 1857854. View

3.
van den Hoogen F, Khanna D, Fransen J, Johnson S, Baron M, Tyndall A . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65(11):2737-47. PMC: 3930146. DOI: 10.1002/art.38098. View

4.
Trojanowska M . Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008; 47 Suppl 5:v2-4. DOI: 10.1093/rheumatology/ken265. View

5.
Mackiewicz Z, Sukura A, Povilenaite D, Ceponis A, Virtanen I, Hukkanen M . Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002; 20(5):641-6. View